Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002109
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Double-Blind Study of Timunox Thymopentin in Asymptomatic HIV-Infected Patients Receiving Either Mono AZT or ddI or Combination AZT ddI or AZT ddC Anti-Retroviral Therapy
Sponsor:
Immunobiology Research Institute
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Double-Blind Study of Timunox Thymopentin in Asymptomatic HIV-Infected Patients Receiving Either Mono AZT or ddI or Combination AZTddI or AZTddC Anti-Retroviral Therapy
Status:
COMPLETED
Status Verified Date:
1996-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To confirm results from a previous study in which the combination of thymopentin plus zidovudine AZT an antiretroviral agent slowed disease progression in HIV-infected asymptomatic patients To evaluate the efficacy and safety of thymopentin in HIV-infected asymptomatic patients receiving either monotherapy with AZT didanosine ddI or stavudine d4T or combination antiretroviral therapy with AZT ddI or AZT zalcitabine ddC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 0732033-93 | None | None | None |